中国临床药理学杂志2017，Vol.33Issue(10)：884-887,4.DOI:10.13699/j.cnki.1001-6821.2017.10.006
重组人生长激素治疗特发性矮小患儿的临床研究
Clinical trial of recombinant human growth hormone in the treatment of children with idiopathic short stature
摘要
Abstract
Objective To observe the clinical efficacy and safety of recombinant human growth hormone in the treatment of children with idiopathic short stature (ISS) and its relationship with vitamin D receptor (VDR) promoter gene polymorphism.Methods A total of 90 cases of ISS children as the treatment group,90 cases of healthy children as the control group.Control group was never given any treatment.Treatment group was given recombinant human growth hormone 0.15 U · kg-1,subcutaneously,once a night for 1 year.The genotype distribution of CDX-2 binding sites with rs11568820 and rs4516035 in the VDR promoter were analyzed by sequencer.The growth velocity (GV),height standard deviation score for age (HtSDScA),height standard deviation score for bone age (HtSDSBA),age peak height velocity (PAH) and adverse drug reaction were compared between two groups in diffrence genotype.Results Among the genotypes of rs3814055 GG,the main indexes in treatment group before and after treatment GV were (3.12 ± 0.32),(9.61 ± 1.01) cm · year-1;,;HtSDScA were (0.29 ± 1.32) ％ (0.93±0.12)％;HtSDSBA were (0.10 ± 0.15)％,(0.86 ± 0.02)％;PAH were (149.02 ± 3.18),(159.02 ±3.21)cm,with significant difference (P ＜ 0.05).Among the genotypes of rs3814055 GA,the main indexes in treatment group before and after treatment,GV were (2.92 ± 1.21),(8.45 ± 1.42)cm · year-1;HtSDScA were (0.42 ±0.15)％,(0.97 ±0.13)％;HtSDSBA were (0.16 ±0.12)％,(0.83 ±0.13)％;PAH were (148.02 ± 3.17),(156.02 ± 3.09) cm,with significant difference (P ＜ 0.05).Among the genotypes of rs11568820 AA,the main indexes in treatment group before and after treatment,GV were (3.27 ± 1.21),(8.21 ± 1.43) cm · year-1;HtSDSCA were (0.37 ±0.14)％, (0.82±0.14)％;HtSDSBA were (0.19 ±0.26),(0.79±0.14)％;PAH were (149.37 ± 2.91),(158.36 ± 2.83) cm,with significant difference (P ＜ 0.05).Among the genotypes of rs4516035 TT,the main indexes in treatment group before and after treatment,GV were (2.71 ± 1.63),(9.32 ±1.21)cm · year-1;;HtSDSCA were (0.35±0.21)％,(0.84±0.13)％;HtSDSBA were (0.17±0.23)％ (0.76 ±0.13) ％;PAH were (151.13 ± 3.15),(158.23 ± 2.86) cm,with significant difference (P ＜ 0.05).Among the genotypes of rs4516035 CT,the main indexes in treatment group before and after treatment,GV were (2.71 ± 1.63),(9.32 ± 1.21) cm · year-t;HtSDSCA were (0.32 ± 0.24) ％,(0.89 ± 0.13) ％;HtSDSBA were (0.17 ± 0.14) ％,(0.72 ± 0.13) ％;PAH were (149.34 ± 3.29),(157.12 ± 3.34) cm,with significant difference (P ＜0.05).The adverse drug reactions in treatment group were based on hyperglycemia (6 cases) and knee pain (4 cases),the incidence was 11.11％.Conclusion There is no significant correlation between ISS and VDR promoter polymorphism,but there is significant correlation with the treatment of recombinant human growth hormone.Recombinant human growth hormone has a definitive clinical efficacy and safety in the treatment of ISS.关键词
重组人生长激素/特发性矮小/维生素D受体启动子/基因多态性Key words
recombinant human growth hormone injection/idiopathic short stature/vitamin D receptor promoter/gene polymorphism分类
医药卫生引用本文复制引用
朱新宇,陈晶..重组人生长激素治疗特发性矮小患儿的临床研究[J].中国临床药理学杂志,2017,33(10):884-887,4.基金项目
厦门市科技计划基金资助项目(350Z20164029) （350Z20164029）
